Bisphosphonate-related osteonecrosis of the jaw (BRONJ) adversely affects the quality of life, producing
significant morbidity. Recently, since the number of osteonecrosis cases involving the maxilla and mandible
associated with other antiresorptive (...
Bisphosphonate-related osteonecrosis of the jaw (BRONJ) adversely affects the quality of life, producing
significant morbidity. Recently, since the number of osteonecrosis cases involving the maxilla and mandible
associated with other antiresorptive (denosumab) and antiangiogenic therapies are growing, the Special Committee
recommends changing the nomenclature of bisphosphonate-related osteonecrosis of the jaw (BRONJ) to the
medication-related osteonecrosis of the jaw (MRONJ). Strategies for management of patients with, or at risk for,
MRONJ were set forth in the American Association of Oral and Maxillofacial Surgeons (AAOMS) updated Position
Paper on Bisphosphonate-Related Osteonecrosis of the Jaws and approved by the Board of Trustees in 2009.
Because it vitally important that this information be disseminated to other relevant health care professionals and
dental professional, I would like to introduce 2014 MRONJ postion paper.